BIOPHYTIS

- EUR (-)

- 15 min delayed data - Euronext Paris

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	ALBPS
ISIN:	FR001400OLP5

BIOPHYTIS overview

> Analyses

Londinia AI has published a new analysis.

0
87390
15394
0

BIOPHYTIS - 1H

Timeframe : 1H - Simple chart
Status : LEVEL MAINTAINED

BIOPHYTIS is part of a very strong bullish trend. Traders may consider trading only long positions (at the time of purchase) as long as the price remains well above 0.7047 EUR. The next resistance…

Thank you Reply Chart

> Analyses

Londinia AI has published a new analysis.

0
87390
15394
0

BIOPHYTIS - Daily

Timeframe : Daily - Simple chart
Status : INVALID

The current short-term bullish trend is expected to quickly reset the neutral or bullish trend. To avoid contradicting the short term, it would be possible to favour long positions (at the time of…

Thank you Reply Chart

> News GlobeNewsWire published a news.

BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile • • GlobeNewsWire • Stocks • More BIOPHYTIS news...

ROMAINVILLE, France, Nov. 30, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS) , a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces the successful completion of its SARA-PK clinical study for Sarconeos, lead drug candidate for the treatment of sarcopenia. The results of the study, conducted in young and elderly healthy volunteers, confirmed Sarconeos’ appropriate safety profile, with no serious adverse events associated with...

Thank you Chart

> News GlobeNewsWire published a news.

BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients • • GlobeNewsWire • Stocks • More BIOPHYTIS news...

ROMAINVILLE, France, Nov. 22, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS) a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces it has received regulatory authorizations in France and Belgium to conduct the SARA-OBS study in sarcopenia patients. Stanislas Veillet, CEO of BIOPHYTIS, said: “We are pleased to obtain these first authorizations, allowing us to initiate recruitment for SARA-OBS in France and Belgium. Additional...

Thank you Chart

> News GlobeNewsWire published a news.

BIOPHYTIS Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting • • GlobeNewsWire • Stocks • More BIOPHYTIS news...

ROMAINVILLE, France, Nov. 15, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS) , a biotechnology company specializing in the development of drug candidates to treat diseases of aging, announced today that four posters on Sarconeos (BIO101), the Company’s lead drug candidate for the treatment of sarcopenia, have been accepted for presentation at the 9th International Conference on Cachexia, Sarcopenia and Muscle Wasting, being held December 10-11, 2016 in Berlin, Germany. Stanislas...

Thank you Chart

> News GlobeNewsWire published a news.

BIOPHYTIS chooses Patheon to produce the clinical batches of Macuneos, its AMD drug candidate that will enter Phase 2B • • GlobeNewsWire • Stocks • More BIOPHYTIS news...

ROMAINVILLE, France, Oct. 24, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging, announced today that it has entered into an agreement with US firm Patheon for the industrial scale-up and manufacturing of clinical batches, the first stage of the Phase 2B clinical trial for drug candidate Macuneos in AMD (age-related macular degeneration). Macuneos is a drug candidate against the dry...

Thank you Chart

Load more content